Avalo Therapeutics, Inc. (AVTX)
NASDAQ: AVTX · IEX Real-Time Price · USD
14.98
+0.78 (5.49%)
At close: Apr 25, 2024, 4:00 PM
16.00
+1.02 (6.81%)
After-hours: Apr 25, 2024, 7:48 PM EDT
Avalo Therapeutics Stock Forecast
AVTX's stock price has decreased by -97.9% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Avalo Therapeutics stock have an average target of 107.5, with a low estimate of 35 and a high estimate of 180. The average target predicts an increase of 617.62% from the current stock price of 14.98.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for AVTX stock from 2 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
---|---|---|---|---|---|---|
Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
Buy | 0 | 0 | 0 | 0 | 0 | 1 |
Hold | 2 | 2 | 2 | 2 | 2 | 1 |
Sell | 1 | 1 | 1 | 1 | 1 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 3 | 3 | 3 | 3 | 3 | 2 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Oppenheimer | Oppenheimer | Hold → Buy Upgrades $35 | Hold → Buy | Upgrades | $35 | +133.64% | Apr 16, 2024 |
Oppenheimer | Oppenheimer | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Jun 27, 2023 |
RBC Capital | RBC Capital | Buy → Hold Downgrades $2,160 → $180 | Buy → Hold | Downgrades | $2,160 → $180 | +1,101.60% | Jun 27, 2023 |
RBC Capital | RBC Capital | Buy Maintains $4,080 → $2,160 | Buy | Maintains | $4,080 → $2,160 | +14,319.23% | May 10, 2023 |
Jefferies | Jefferies | Hold → Sell Downgrades $720 | Hold → Sell | Downgrades | $720 | +4,706.41% | Feb 8, 2023 |
Financial Forecast
Revenue This Year
1.22M
from 1.92M
Decreased by -36.38%
Revenue Next Year
1.02M
from 1.22M
Decreased by -16.67%
EPS This Year
-17.14
from -114.00
EPS Next Year
-17.14
from -17.14
Revenue Forecast
Revenue | 2024 | 2025 | 2026 | 2027 |
---|---|---|---|---|
High | 1.3M | 1.1M | 1.1M | 1.1M |
Avg | 1.2M | 1.0M | 1.0M | 1.0M |
Low | 1.2M | 980,000 | 980,000 | 980,000 |
Revenue Growth
Revenue Growth | 2024 | 2025 | 2026 | 2027 |
---|---|---|---|---|
High | -34.5% | -14.2% | 2.9% | 2.9% |
Avg | -36.4% | -16.7% | - | - |
Low | -38.9% | -19.9% | -3.9% | -3.9% |
EPS Forecast
EPS | 2024 | 2025 | 2026 |
---|---|---|---|
High | -17.64 | -17.64 | -17.64 |
Avg | -17.14 | -17.14 | -17.14 |
Low | -16.46 | -16.46 | -16.46 |
EPS Growth
EPS Growth | 2024 | 2025 | 2026 |
---|---|---|---|
High | - | - | - |
Avg | - | - | - |
Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.